Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.

Naidoo J., Vansteenkiste J. F., Faivre-Finn C., Özgüroğlu M., Murakami S., Hui R., ...Daha Fazla

Lung cancer (Amsterdam, Netherlands), cilt.166, ss.84-93, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 166
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.lungcan.2022.02.003
  • Dergi Adı: Lung cancer (Amsterdam, Netherlands)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.84-93
  • Anahtar Kelimeler: Locally advanced NSCLC, Pneumonitis, Immune checkpoint inhibition, Thyroid disorders, Chemoradiotherapy, PACIFIC, PNEUMONITIS, DOCETAXEL, NIVOLUMAB, PEMBROLIZUMAB, CHEMOTHERAPY, INHIBITOR, ANTI-PD-1
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Introduction: Immune-mediated adverse events (imAEs), including all-cause immune-mediated pneumonitis, were reported in approximately 25% of patients in the placebo-controlled, phase III PACIFIC trial of durvalumab monotherapy (for up to 12 months) in patients with unresectable, stage III NSCLC and no disease progression after concurrent chemoradiotherapy; only 3.4% of patients experienced grade 3/4 imAEs. With broad application of the PACIFIC regimen (consolidation durvalumab after chemoradiotherapy), now standard-of-care in this setting, there is a need to better characterize the occurrence of imAEs with this regimen.